Authors: Stergios A Polyzos Evangelos Terpos
Publish Date: 2016/07/08
Volume: 54, Issue: 1, Pages: 271-272
Abstract
Denosumab treatment has an established antifracture efficacy for osteoporosis but there is recent concern for increased vertebral fracture risk following its discontinuation We would like to present our clinical experience adding two new cases of clinical vertebral fractures following denosumab discontinuation Informed consent was obtained from both participants included in the studyA 62year woman was presented March 2016 after a lowenergy vertebral L3 fracture December 2015 which caused prolonged severe pain She was treatment naive when osteoporosis complicated with a previous asymptomatic vertebral fracture T8 was diagnosed April 2013 and she received four denosumab injections 60 mg but no calcium and vitamin D supplementation In April 2015 her physician discontinued denosumab after bone mineral density BMD improvement The fracture occurred 14 months after the last denosumab injection At presentation her serum calcium 91 mg/dl phosphate
Keywords: